STOCK TITAN

Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2 at 9:00 a.m. ET. The session will be accessible via a live webcast on the company's Investors page, with an archived version available afterward. Merus focuses on developing innovative multispecific antibodies, particularly its Biclonics® and Triclonics® products, which aim to advance cancer treatment.

Loading...
Loading translation...
Argus Session date unavailable
-0.24% session move Open Argus
Details

News Market Reaction – MRUS

The recorded move for MRUS in the trading session of this news was -0.24%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m. ET.

The live webcast of the presentation will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

Investor and Media Inquiries:

Kathleen Farren
Merus N.V.
Communications Specialist
617-230-4165
k.farren@merus.nl


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event will Merus N.V. participate in on June 2, 2021?

Merus N.V. will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021.

Who is the CEO of Merus N.V.?

The CEO of Merus N.V. is Bill Lundberg, M.D.

Where can I watch the Merus N.V. presentation from the Jefferies Conference?

The presentation can be watched via a live webcast on the Investors page of Merus N.V.'s website.

What type of antibodies does Merus N.V. develop?

Merus N.V. develops innovative full-length multispecific antibodies known as Biclonics® and Triclonics®.

Keep reading